Loading page
Loading page
Loading substance route
Doses are highly variable between individuals due to differences in alcohol dehydrogenase activity. Effects are delayed compared to GHB; redosing before onset is a common cause of overdose.
Effects vary widely by individual, dose, and context.
The physical effects of 1,4-butanediol can be broken down into several components which progressively intensify proportional to dosage.
The cognitive effects of 1,4-butanediol can be broken down into several components which progressively intensify proportional to dosage. It contains a large number of typical depressant cognitive effects.
Classified as habit-forming with potential for psychological dependence characteristic of GABAergic depressants.
Safe only in small amounts; death is possible if ingested in large quantities. A 2021 poisoning incident in Germany involving contaminated beverages resulted in several severe illnesses, with one person in critical condition.
Liver toxicity has been identified as a potential health risk associated with use, representing an additional hazard compared to GHB itself.
1,4-Butanediol was first synthesized in 1890 by Dutch chemist Pieter Johannes Dekkers through the acidic hydrolysis of N,N'-dinitro-1,4-butanediamine. Dekkers originally named the compound "tetramethylene glycol," a reference to its structure as a four-carbon diol.
Controlled as a Schedule VI precursor under the Controlled Drugs and Substances Act. This classification applies to precursor chemicals rather than substances controlled for direct psychoactive effects.
Scheduled in December 2009 as a Class C controlled substance alongside gamma-butyrolactone (GBL), another GHB precursor. Controlled under the Misuse of Drugs Act 1971.
The substance is not explicitly listed as illegal under German drug legislation. However, it may be treated as illegal if possessed or sold for use as a drug rather than for legitimate industrial purposes.
While 1,4-butanediol is not currently scheduled at the federal level, several states have classified it as a controlled substance. Individuals have been prosecuted for possession under the Federal Analog Act as substantially similar to GHB. Court rulings have been inconsistent: a 2002 federal case in New York ruled it could not be considered a GHB analog, but this decision was later overturned by the Second Circuit Court of Appeals.
16 sources cited
